Aliskiren add-on therapy effectively reduces proteinuria in chronic kidney disease: An open-label prospective trial

作者：Wu Men Tai; Tung Shi Cheng; Hsu Kao Tai; Lee Chien Te^*

来源：Journal of the Renin-Angiotensin-Aldosterone System, 2014, 15(3): 271-277.

DOI：10.1177/1470320312467560

• Aliskiren
• proteinuria
• chronic kidney disease

Introduction: The combination therapy of aliskiren and renin-angiotensin-aldosterone system (RAAS) blocker in chronic kidney disease (CKD) is controversial. Whether such dual blockade can effectively apply to patients with CKD irrespective of stage and amount of proteinuria remains uncertain. %26lt;br%26gt;Methods: We added aliskiren at a dosage of 150 mg/day for six months in 103 Chinese CKD patients who had been treated with angiotensin converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) and still had significant proteinuria or uncontrolled hypertension. Blood pressure, serum creatinine, estimated glomerular filtration rate (eGFR), potassium, and spot urine protein-to-creatinine ratio (UPCR) were measured at three and six months after aliskiren add-on therapy and compared with baseline. %26lt;br%26gt;Results: The combination of aliskiren and ACEi or ARB significantly reduced UPCR by 23% (p=0.001) and mean arterial pressure by 7.9 13.8 mmHg (p%26lt;0.001) at six months. Twenty-five percent of subjects had a greater than 50% reduction in UPCR. No significant changes in eGFR and serum potassium level were noted at six months. %26lt;br%26gt;Conclusions: Adding aliskiren on ACEi or ARB in CKD patients, both in diabetes and non-diabetes, has a favorable effect on reducing residual proteinuria and inadequately controlled blood pressure.

• 出版日期2014-9
• 单位长春大学